Dr. René C.-Gaudreault, l. pharm., PhD, is a senior researcher at the Centre de recherche du CHU de Québec-Laval University. He is the director of a medicinal chemistry laboratory based at the Hôpital Saint-François d’Assise. In addition, he is a full professor in the Department of molecular medicine at the Laval University School of Medicine. Dr. C.-Gaudreault is the author and coauthor of over 100 publications in peer-reviewed journals, and the inventor and co-inventor of numerous patents. He is the recipient of several prizes and distinctions, notably the Frisen-Rygel Medal for an outstanding Canadian academic discovery leading to uniquely positioned commercialization opportunities. His research programs mainly focus on the design and development of new anti-inflammatory, antipsoriatic, and anticancer drugs for personalized therapies.
Development of new anticancer and anti-inflammatory drugs for personalized medicine
Cancer and inflammation-based diseases are major health concerns in Canada and worldwide. Despite important medical breakthroughs over the past 75 years, few treatments are efficient and devoid of deleterious effects. Consequently, new drugs and treatments are required to improve both the quality of life and the life expectancy of patients. It is in this context that Dr. Gaudreault’s laboratory is involved in the drug design and development of new anticancer agents and their prodrugs, and non-steroidal anti-inflammatory agents exhibiting suitable biopharmaceutical and pharmacodynamic properties for preclinical and clinical studies. In addition, Dr. Gaudreault’s team is involved in the determination of their mechanisms of action and their potential therapeutical applications, using various cellular and molecular pharmacology approaches to support the design and the optimization of the next generations of molecules. Dr. Gaudreault’s research programs involve several interrelated and complementary disciplines, including molecular design and modelling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to new and efficient drugs for applications in personalized medicine.
10, rue de l'Espinay
Canada G1L 3L5
Evaluation of the time-dependent antiproliferative activity and liver microsome stability of 3 phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as promising CYP1A1-dependent antimicrotubule prodrugs.Journal Article
J Pharm Pharmacol, 2019, ISSN: 0022-3573.
Second-generation testosterone-platinum(II) hybrids for site-specific treatment of androgen receptor positive prostate cancer: Design, synthesis and antiproliferative activity.Journal Article
Eur J Med Chem, 179 , pp. 660-666, 2019, ISSN: 0223-5234.
Transdermal diffusion, spatial distribution and physical state of a potential anticancer drug in mouse skin as studied by diffusion and spectroscopic techniquesJournal Article
Biomed Spectrosc Imaging, 7 (1-2), pp. 47-61, 2018, ISSN: 2212-8794.
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells.Journal Article
J Med Chem, 60 (12), pp. 4963-4982, 2017, ISSN: 0022-2623.
Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity.Journal Article
Bioorg Med Chem Lett, 27 (2), pp. 299-302, 2017, ISSN: 0960-894X.
Discovery of ethyl urea derivatives as inhibitors of islet amyloid polypeptide fibrillization and cytotoxicity.Journal Article
Can J Physiol Pharmacol, 94 (3), pp. 341-6, 2016, ISSN: 0008-4212.
Synthesis of novel C2-symmetric testosterone dimers and evaluation of antiproliferative activity on androgen-dependent and -independent prostate cancer cell lines.Journal Article
Steroids, 115 , pp. 98-104, 2016, ISSN: 0039-128X.
Size-Controlled Functionalized Mesoporous Silica Nanoparticles for Tunable Drug Release and Enhanced Anti-Tumoral ActivityJournal Article
Chem Mater, 28 (12), pp. 4243-4258, 2016, ISSN: 0897-4756.
Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model.Journal Article
Eur J Med Chem, 100 , pp. 34-43, 2015, ISSN: 0223-5234.
Microtubule disrupting N-phenyl-N’-(2-chloroethyl)ureas display anticancer activity on cell adhesion, p-glycoprotein and BCL-2-mediated drug resistance.Journal Article
Int J Pharm Pharm Sci, 6 (2), pp. 171-179, 2014.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
- Substituted phenyl alkylureas as new potent antipsoriatic drugs: Mechanism of action and structure-activity relationships., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2020-06-30
- Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2018-04-01 to 2021-03-31
Recently finished projects
- Comprendre le rôle des cellules immunitaires dans le psoriasis grâce au génie tissulaire, Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2019-03-31
- Les phénylimidazolidones, de nouvelles molécules pour le traitement personnalisé des cancers du sein hormono- et chimiorésistants: du laboratoire vers la clinique., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2019-07-30